根据不良反应评估结果,为控制药品使用风险,国家食品药品监督管理局(SFDA)于2012年5月18日发布通知,决定对盐酸拉莫三嗪口服制剂的说明书的警示语、不良反应、注意事项进行修订。 According to the results of the adverse reaction assessment, in order to control the risk of drug use, the SFDA issued a circular on May 18, 2012 to determine the warnings and adverse reactions to the instructions for the oral formulation of lamotrigine hydrochloride. Matters to be revised.